Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - Restoration by exogenous interleukin-12

Clinical and Experimental Immunology

Volumn 130, Issue 1, 2002, Pages 107-114

  Lohr H F ^a   Pingel, S ^a   Bocher W O ^a   Bernhard, H ^b   Herzog Hauff, S ^a   Rose John, S ^c   Galle, P R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

Antigen presentation; Chronic hepatitis B; Dendritic cells; Viral persistence interleukin 12

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RECOMBINANT INTERLEUKIN 12; STEM CELL FACTOR; TETANUS TOXOID; VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INCUBATION TIME; LYMPHOCYTE CULTURE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; PERSISTENT VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; T LYMPHOCYTE ACTIVATION; VIRUS CARRIER; VIRUS IMMUNITY;

ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CONVALESCENCE; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-6; LYMPHOKINES; RECOMBINANT FUSION PROTEINS; STEM CELL FACTOR; T-LYMPHOCYTES, HELPER-INDUCER; TETANUS TOXOID;

EID: 0036378341     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01943.x     Document Type: Article

References (46)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13:29-60.
2. Lau GKK, Lok ASF, Liang RHS et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immune transfer. Hepatology 1997; 25:1497-501.
3. Moriyama T, Guilhot S, Klopchin K et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248:361-4.
4. Guidotti LG, Ando K, Hobbs MV et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a non-cytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91:3764-8.
5. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284:825-9.
6. Löhr HF, Weber W, Schlaak J, Goergen B, Meyer zum Büschenfelde KH, Gerken G. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 1995; 22:61-8.
7. Nayersina R, Fowler P, Guilhot S et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150:4659-71.
8. Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:1565-70.
9. Böcher WO, Herzog-Hauff S, Schlaak J, Meyer zum Büschenfelde K-H, Löhr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999; 29:238-44.
10. Löhr HF, Krug S, Herr W et al. Quantitative and functional analysis of core specific T helper cell and CTL activities in acute and chronic hepatitis B. Liver 1998; 18:413-24.
11. Löhr HF, Gerken G, Schlicht HJ, Meyer zum Büschenfelde KH, Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenously processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993; 168:1133-9.
12. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus specific CD8+ T cells associated with the control of infection. Gastroenterology 1999; 117:1386-96.
13. Diepolder HM, Jung MC, Keller E et al. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998; 113:244-51.
14. Höhler T, Gerken G, Notghi A et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26:503-7.
15. Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde K-H. The presence of high amounts of HBeAg in serum is associated with suppressive costimulatory effects of interleukin-12 on HBV induced immune responses. J Hepatol 1999; 30:353-8.
16. Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF. Clinical and immunologocal efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002; 66:452-60.
17. Rahman F, Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31:521-7.
18. Akbar SMF, Inaba K, Onji M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-γ: Abrogation of immune response defect to a T-cell-dependent antigen. Immunology 1996; 87:519-27.
19. Hsu FJ, Benike C, Fagnoni F et al. Vaccinations of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2:52-8.
20. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4+ T cells. J Exp Med 1997; 185:2133-41.
21. Strobl H, Riedl E, Bello-Fernandez C, Knapp W. Epidermal Langerhans Cell development and differentiation. Immunobiology 1998; 198:588-605.
22. Akbar SMF, Horiike N, Onji M. Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. Immunology 1999; 96:98-108.
23. Meierhoff G, Krause SW, Andreesen A. Comparative analysis of dendritic cells derived from blood monocytes or CD34+ hematopoietic progenitor cells. Immunobiology 1998; 198:501-13.
24. Motarini R, Anichini A, Di Nicola M et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/MART-1 (27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997; 57:5534-41.
25. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
26. Bernhard H, Lohmann M, Batten WY et al. The gp130-stimulating designer cytokine Hyper-IL-6 promotes the expansion of functional dendritic cells from CD34+ hematopoietic progenitor cells. Exp Hematol 2000; 28:365-72.
27. Fischer MJ, Goldschmitt C, Peschel C et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997; 15:142-7.
28. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 36:258-61.
29. Sallusto FM, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 1995; 182:389-400.
30. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor-alpha. J Exp Med 1994; 179:1104-18.
31. Ahuja SS, Reddick RL, Sato N et al. Dendritic cell (DC) -based anti-infective strategies. DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999; 163:3890-7.
32. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 1999; 93:2411-9.
33. Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Strokus WJ. HIV-1 specific CTL responses primed in vitro by blood derived dendritic cells and Th1-biasing cytokines. J Immunol 1999; 162:3070-8.
34. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968-75.
35. Mason A, Yoffe B, Noonan C et al. Hepatitis B virus DNA in peripheral blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology 1992; 16:36-41.
36. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 1999; 20:561-7.
37. Diepolder HM, Jung MC, Wierenga EA et al. Anergic Th1 clones specific for hepatitis B virus core peptides are inhibitory to other HBV-core specific CD4+ T cells in vitro. J Virol 1996; 70:7540-8.
38. Schnorr JJ, Xanthakos S, Keikavoussi P et al. Induction of maturation of human blood derived dendritic cell precursors by measles virus is associated with immunosuppression. Proc Natl Acad Sci USA 1997; 94:5326-34.
39. Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk A. Interleukin-10 treated human dendritic cells induce a melanoma-antigen specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999; 93:1634-42.
40. Bhardwaj N, Seder RA, Reddy A, Feldman MV. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J Clin Invest 1996; 98:715-22.
41. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML. Human dendritic cells require exogenous interleukin-12 inducing factors to direct the development of naïve T-helper toward the Th1 phenotype. Blood 1997; 90:1920-6.
42. Kalinski P, Schuitemaker JHN, Hilkens CMU, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999; 162:3231-6.
43. Nagayama H, Sato K, Kawasaki H et al. IL-12 responsiveness and expression of IL-12 receptor in human peripheral blood monocyte-derived dendritic cells. J Immunol 2000; 165:59-66.
44. Macatonia SE, Hosken NA, Litton M et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naïve CD4+ T cells. J Immunol 1995; 154:5071-9.
45. Merad M, Angevin E, Wolfers T et al. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: Modulation of their functional properties after therapy with biological response modifiers. J Immunotherapy 2000; 23:369-78.
46. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC. Uptake of Leishmania major amastigotes results in activation and interleukin-12 release from murine skin-derived dendritic cells: Implications for the initiation of anti-Leishmania immunity. J Exp Med 1998; 188:1547-52.